MétaCan
Menu
Retour à la cohorte
Enregistrement W2204744204 · doi:10.1016/j.ebiom.2015.11.033

Tuning WNT-β-catenin signaling via BCL9 proteins for targeting colorectal cancer cells

2015· letter· en· W2204744204 sur OpenAlexaff
Jean‐François Beaulieu

Notice bibliographique

RevueEBioMedicine · 2015
Typeletter
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueWnt/β-catenin signaling in development and cancer
Établissements canadiensUniversité de Sherbrooke
Organismes subventionnairesnon disponible
Mots-clésWnt signaling pathwayAdenomatous polyposis coliCancer researchBiologyCateninBeta-cateninCell biologySignal transductionEnhancerLRP6Colorectal cancerTranscription factorCancerGeneticsGene

Résumé

récupéré en direct d'OpenAlex

The canonical WNT signaling pathway is ultimately involved in the regulation of cytoplasmic levels of free β-catenin. When inactive, the β-catenin not incorporated in adherent junctions is captured by the adenomatous polyposis coli (APC)-based protein complex, phosphorylated and then processed for degradation by the proteasome. Activation by WNT ligands such as those found in the intestinal stem cell niche located in the lower crypts prevents β-catenin ubiquitination allowing its accumulation in the cytoplasm and shuttling to the nucleus where it associates with the DNA-binding proteins of the lymphoid enhancer-binding factor/T-cell factor (TCF) family to transactivate specific gene expression such as MYC, CCLD1 and other genes that drive cell proliferation and stemness (Niehrs, 2012Niehrs C. The complex world of WNT receptor signalling.Nat. Rev. Mol. Cell Biol. 2012; 13: 767-779http://dx.doi.org/10.1038/nrm3470Crossref PubMed Scopus (976) Google Scholar). Colorectal cancer (CRC) cells frequently display a constitutively active WNT–β-catenin signaling pathway as a consequence of mutations in APC or other genes that encode the APC-based protein destruction complex or β-catenin itself, which allows β-catenin to accumulate in the nucleus and contribute to cellular transformation (Barker and Clevers, 2006Barker N. Clevers H. Mining the Wnt pathway for cancer therapeutics.Nat. Rev. Drug Discov. 2006; 5: 997-1014http://dx.doi.org/10.1038/nrd2154Crossref PubMed Scopus (647) Google Scholar, Krausova and Korinek, 2014Krausova M. Korinek V. Wnt signaling in adult intestinal stem cells and cancer.Cell. Signal. 2014; 26: 570-579http://dx.doi.org/10.1016/j.cellsig.2013.11.032Crossref PubMed Scopus (282) Google Scholar). There are many factors that interact and modulate the WNT cascade in both normal and transformed cells. As depicted in seminal reviews (Cruciat and Niehrs, 2013Cruciat C.M. Niehrs C. Secreted and transmembrane wnt inhibitors and activators.Cold Spring Harb. Perspect. Biol. 2013; 5: a015081http://dx.doi.org/10.1101/cshperspect.a015081Crossref PubMed Scopus (426) Google Scholar, de Lau et al., 2014de Lau W. Peng W.C. Gros P. Clevers H. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength.Genes Dev. 2014; 28: 305-316http://dx.doi.org/10.1101/gad.235473.113Crossref PubMed Scopus (421) Google Scholar), WNT signaling is strictly controlled at the ligand–receptor level by a series of inhibitors and activators that regulate signal strength. Furthermore, WNT signaling is also modulated at the transcriptional level by a series of β-catenin-interacting co-factors such as cyclic AMP response element-binding protein and B-cell lymphoma 9 (BCL9 and BCL9L) which can strengthen the activity (Holland et al., 2013Holland J.D. Klaus A. Garratt A.N. Birchmeier W. Wnt signaling in stem and cancer stem cells.Curr. Opin. Cell Biol. 2013; 25: 254-264http://dx.doi.org/10.1016/j.ceb.2013.01.004Crossref PubMed Scopus (383) Google Scholar). While many of these modulators of the WNT pathway represent potential targets for cancer therapeutics, their disruption can also lead to alterations in the WNT signaling pathway of healthy tissues, a difficulty that has to be taken into consideration in the design of pre-clinical and, eventually, clinical studies (Barker and Clevers, 2006Barker N. Clevers H. Mining the Wnt pathway for cancer therapeutics.Nat. Rev. Drug Discov. 2006; 5: 997-1014http://dx.doi.org/10.1038/nrd2154Crossref PubMed Scopus (647) Google Scholar). In this context, it is interesting to note that the impact of the cellular response associated with the β-catenin co-factor BCL9/9L may be context-dependent. Indeed, in the mouse, ablation of Bcl9/9l in the intestinal epithelium abrogates the expression of genes related to epithelial–mesenchymal transformation (EMT) and stemness in chemically induced colorectal tumors suggesting that the traits associated with tumor invasion and metastasis via Bcl9/9l appear to be dispensable for normal intestinal epithelial homeostasis (Deka et al., 2010Deka J. Wiedemann N. Anderle P. Murphy-Seiler F. Bultinck J. Eyckerman S. Stehle J.C. Andre S. Vilain N. Zilian O. Robine S. Delorenzi M. Basler K. Aguet M. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.Cancer Res. 2010; 70: 6619-6628http://dx.doi.org/10.1158/0008-5472.CAN-10-0148Crossref PubMed Scopus (107) Google Scholar). In this issue of EBioMedicine, Moor et al. have further investigated the importance of BCL9/9L on WNT signaling in CRC cells (Moor et al., 2015Moor A.E. Anderle P. Cantù C. Rodriguez P. Wiedemann N. Baruthio F. Deka J. André S. Valenta T. Moor M.B. Győrffy B. Barras D. Delorenzi M. Basler K. Aguet M. BCL9/9L-β-catenin signaling is associated with poor outcome in colorectal cancer.EBioMedicine. 2015; 2: 1932-1942Summary Full Text Full Text PDF PubMed Scopus (46) Google Scholar). They first investigated a second CRC mouse model driven by loss of Apc and oncogenic Kras to complement their initial observations performed on the chemically induced mouse CRC model mentioned above (Deka et al., 2010Deka J. Wiedemann N. Anderle P. Murphy-Seiler F. Bultinck J. Eyckerman S. Stehle J.C. Andre S. Vilain N. Zilian O. Robine S. Delorenzi M. Basler K. Aguet M. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.Cancer Res. 2010; 70: 6619-6628http://dx.doi.org/10.1158/0008-5472.CAN-10-0148Crossref PubMed Scopus (107) Google Scholar) confirming that ablation of Bcl9/9l modulates similar alterations of gene expression in both types of tumors with 359 down- and 107 up-regulated common differentially expressed genes. Analysis of the up- and down-regulated genes revealed a negative enrichment of genes related to intestinal WNT targets, stemness and EMT while differentiation-related genes were positively enriched. Interestingly, a search for human homologs allowed the characterization of a BCL9/9L-KO signature of 378 genes that was then used to probe public human CRC databases revealing that hazards of relapse and death are both significantly reduced in patients displaying BCL9/9L-KO-like tumor profiles. Then, using the organoid/mini-gut culture system consisting of expanding epithelial stem cells isolated from the intact intestine into three-dimensional structures (Sato and Clevers, 2013Sato T. Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications.Science. 2013; 340: 1190-1194http://dx.doi.org/10.1126/science.1234852Crossref PubMed Scopus (777) Google Scholar), they confirmed that ablation of Bcl9/9l improves morphological differentiation and generates a BCL9/9L KO-like signature without altering proliferation in vitro. Interestingly, subcutaneous grafting of the same organoids in immuno-compromised mice resulted in tumor regression in allografts lacking Bcl9/9l while the wild-type organoids grew exponentially, consistent with their Apc−/− and mutated Kras background. Taken together, these results suggest that CRC cells are very dependent on functional BCL9 proteins for promoting tumor progression via stimulation of stemness and EMT traits and preventing differentiation, a pathway not apparently essential for the maintenance of normal intestinal epithelial homeostasis. The discovery that patients with tumors displaying gene expression profiles similar to the BCL9/9L-KO signature have a better prognosis than those with a BCL9/9L wild-type phenotype is quite relevant to these findings. While this points out the interest of the β-catenin–BCL9/9L complex as a potential therapeutic target for CRC, it also raises the need to validate, in the end, the direct implication of BCL9/9L in the generation of the BCL9/9L-KO signature in human cells, considering the fact that BCL9/9L have been found to be expressed in all tumor samples. Another key aspect that remains to be investigated pertains to the possibly distinct implications of BCL9 and BCL9L. The findings from human CRC database analyses that stemness traits appear to correlate much more closely with BCL9L than BCL9 is noteworthy particularly in the context where in the mouse, BCL9L over-expression appears to induce intestinal tumorigenesis and promote expression of genes involved in EMT (Brembeck et al., 2011Brembeck F.H. Wiese M. Zatula N. Grigoryan T. Dai Y. Fritzmann J. Birchmeier W. BCL9-2 promotes early stages of intestinal tumor progression.Gastroenterology. 2011; 141 (1370 e1351-1353)http://dx.doi.org/10.1053/j.gastro.2011.06.039PubMed Google Scholar). In summary, the results by Moor et al. show that inhibiting the BCL9/9L interaction with β-catenin leads to diminished gene expression associated with stemness and EMT traits and promotes differentiation in CRC tumors (in the context as shown previously (Deka et al., 2010Deka J. Wiedemann N. Anderle P. Murphy-Seiler F. Bultinck J. Eyckerman S. Stehle J.C. Andre S. Vilain N. Zilian O. Robine S. Delorenzi M. Basler K. Aguet M. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.Cancer Res. 2010; 70: 6619-6628http://dx.doi.org/10.1158/0008-5472.CAN-10-0148Crossref PubMed Scopus (107) Google Scholar) that it remains relatively well tolerated in the normal intestinal epithelium). Taken in conjunction with the fact that the BCL9/9L-KO signature in CRC tumors is associated with a better prognosis, the study points out that the BCL9/9L–β-catenin complex represents a promising potential therapeutic target for treating CRC. The author declares no conflicts of interest. BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal CancerBCL9/9L proteins enhance the transcriptional output of the β-catenin/TCF transcriptional complex and contribute critically to upholding the high WNT signaling level required for stemness maintenance in the intestinal epithelium. Here we show that a BCL9/9L-dependent gene signature derived from independent mouse colorectal cancer (CRC) models unprecedentedly separates patient subgroups with regard to progression free and overall survival. We found that this effect was by and large attributable to stemness related gene sets. Full-Text PDF Open Access

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,001
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesMéta-épidémiologie (sens strict)
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Expérimental (laboratoire) · Signal consensuel: aucune
GenreSignal candidat: Commentaire · Signal consensuel: Commentaire
Score de désaccord entre enseignants0,141
Score d'incertitude au seuil1,000

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0010,000
Méta-épidémiologie (sens strict)0,0010,001
Méta-épidémiologie (sens large)0,0010,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0010,000
Intégrité de la recherche0,0010,001
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,017
Tête enseignante GPT0,262
Écart entre enseignants0,245 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeExpérimental (laboratoire)
Domainenon disponible
GenreCommentaire

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations4
Publié2015
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueEBioMedicineMême sujetWnt/β-catenin signaling in development and cancerTravaux en français237 207